A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia

Comparison of Two Strategies for Prophylactic Donor Lymphocyte Infusion in Patients With Refractory/Relapsed Acute Leukemia

(2021) Qiongqiong Su et al.   Frontiers in Oncology

Emerging agents and regimens for AML

(2021) Hongtao Liu   Journal of Hematology & Oncology

Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes

(2021) Sijian Yu et al.   JAMA Network Open

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions

(2020) Ahmad I. Antar et al.   LEUKEMIA

How I Treat Relapsed or Refractory AML

(2020) Susan E DeWolf et al.   BLOOD

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)

(2020) Andreas Burchert et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

(2020) Li Xuan et al.   LANCET ONCOLOGY

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

(2020) Musa Yilmaz et al.   Journal of Hematology & Oncology

Sorafenib prevents AML relapse after allo-HSCT

(2020) Diana Romero   Nature Reviews Clinical Oncology

Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation

(2019) Li Xuan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Ponatinib therapy in recurrent Philadelphia chromosome‐positive central nervous system leukemia with T315I mutation after Allo‐HSCT

(2019) Jia‐Bao He et al.   INTERNATIONAL JOURNAL OF CANCER

Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/Refractory Acute Myeloid Leukemia

(2018) Nan Yang et al.   Anti-Cancer Agents in Medicinal Chemistry

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

(2018) Li Xuan et al.   CANCER

Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier

(2018) Janice K. Laramy et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

(2018) Nimitha R Mathew et al.   NATURE MEDICINE

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

(2015) Madan H. Jagasia et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

(2015) Christoph Röllig et al.   LANCET ONCOLOGY

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

(2013) F. Ravandi et al.   BLOOD

Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells

(2013) Martin Franz Sprinzl et al.   HEPATOLOGY

Brain Metastases from Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors

(2012) Arkadiusz Z. Dudek et al.   Clinical Genitourinary Cancer

Revisiting the role of molecular targeted therapies in patients with brain metastases

(2011) Dionysis Papadatos-Pastos et al.   JOURNAL OF NEURO-ONCOLOGY

Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma

(2010) N. Gokbuget et al.   HAEMATOLOGICA

Impact of Cranial Irradiation Added to Intrathecal Conditioning in Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia With Central Nervous System Involvement

(2010) Jyoti S. Mayadev et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

The Role of the Breast Cancer Resistance Protein (ABCG2) in the Distribution of Sorafenib to the Brain

(2010) S. Agarwal et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

(2010) K W Pratz et al.   LEUKEMIA

Incidence of brain metastases in renal cell carcinoma treated with sorafenib

(2009) C. Massard et al.   ANNALS OF ONCOLOGY

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

(2008) K. Porkka et al.   BLOOD

Current management and challenges of malignant disease in the CNS in paediatric leukaemia

(2008) Ching-Hon Pui et al.   LANCET ONCOLOGY

Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: Results from the GET-LALA group

(2008) Oumedaly Reman et al.   LEUKEMIA RESEARCH